期刊
EPIGENOMICS
卷 13, 期 11, 页码 829-844出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2021-0078
关键词
biomarker; colon; DNA methylation; epigenetics; intestine; methylome; necrotizing enterocolitis; neonatal; prematurity; stool
资金
- Pediatric Loan Repayment Program from the NIH, March of Dimes Foundation [5-FY17-79]
- Children's Discovery Institute of Washington University in St. Louis
- St. Louis Children's Hospital Foundation
- Department of Pediatrics at Washington University School of Medicine
- NIH [5T32HD043010]
- Pittsburgh Health Data Alliance (PHDA)
- Magee-Women's Research Institute
- Astarte Medical Partners
- Takeda Pharmaceuticals
- Evive Biotech, Inc
- [K08DK101608]
- [R03DK111473]
- [R01DK118568]
This study identified significant genomic hypermethylation in NEC tissues compared to non-NEC controls, particularly in regions outside CpG islands and gene regulatory elements. The findings suggest a specific methylomic signature associated with NEC that can be detected noninvasively, providing a new opportunity for the development of a novel diagnostic method for NEC.
Aim: Neonatal necrotizing enterocolitis (NEC) is a deadly and unpredictable gastrointestinal disease, for which no biomarker exists. We aimed to describe the methylation patterns in stool and colon from infants with NEC. Methods: We performed a high-resolution genome-wide epigenomic analysis using solution-phase hybridization and next-generation sequencing of bisulfite-converted DNA. Results: Our data reveal significant genomic hypermethylation in NEC tissues compared with non-NEC controls. These changes were more pronounced in regions outside CpG islands and gene regulatory elements, suggesting that NEC-specific hypermethylation is not a nonspecific global phenomenon. Conclusions: This study provides evidence of a methylomic signature associated with NEC that is detectable noninvasively and provides a new opportunity for the development of a novel diagnostic method for NEC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据